Palatin Technologies, Inc. (PTN) Reports Q1 Loss of $0.04; Updates Bremelanotide Development. Article Related Press Releases (1) Stock Quotes (1) Comments (0).

PRINCETON, NJ (February 15, 2002) - Palatin Technologies Inc (AMEX:PTN) today announced results for its second quarter ended December 31, 2001.

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Is Palatin Technologies, Inc. (NYSEAMEX:PTN) undervalued? Investors who are in the know are becoming hopeful. The number of long hedge fund bets rose by 1 lately.

CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and ...

(RTTNews.com) - Palatin Technologies Inc.( PTN ) will host a conference call at 11:00 AM ETMay 14, 2013, to discuss its Q3 13 earnings results.

New York, NY - (NISMAGAZINE) - 05/02/2013- Exide Technologies (NASDAQ:XIDE) shares decreased 9.94% to $0.713 from its previous close of $0.79.

... 0.00 -0.02 -0.02 26.2 23.7 -2.5 PALATIN TECHNOLOGIES INC Q3 LEISURE USD -0.06 -0.04 0.02 0.0 0.0 0.0 PAN AMERICAN SILVER CORP Q1 PRECIOUS METALS USD 0.24 0.26 0.02 260.3 243.0 -17.3 PAN AMERICAN SILVER CORP Q1 PRECIOUS ...

Palatin Technologies, Inc. ( PTN ) is reporting for the quarter ending March 31, 2013. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.05.

What They Do: Mattson Technology, Inc. designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits.